Molecular Diagnostics Market Overview:

Global Molecular Diagnostics Market was valued at $5,962 million in 2016, and is expected to garner $10,557 million by 2023, registering a CAGR of 9.1% during the forecast period 2017-2023. Molecular diagnostic tests are used to detect specific sequences in DNA or RNA, including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others to further diagnose the disease. These are cumulative techniques for analyzing biological markers at the molecular level, such as genome and proteome. These techniques are used for diagnosis of the various infectious diseases, cancer, and others and is also used to check the genetic predisposition to a disease.

The factors such increase in the prevalence of the infectious diseases and various types of cancer, increase in awareness and acceptance of personalized medicines, growth in the biomarker identification, and advancement in molecular diagnostics drive the market growth. Stringent regulatory requirements for the approval of new molecular diagnostics techniques hampers the growth of the market. However, increase in adoption of the molecular diagnostics in the emerging economies provide growth opportunities for the market.

The global molecular diagnostics market is segmented based on type, technology, application, end user, and geography. Based on type, it is classified into instruments, reagents, and software & services. The reagents segment contributed the highest share in 2016, owing to the rise in demand for solutions, quality control reagents, and different reagents for different tests. Based on technology, it is categorized into polymerase chain reaction (PCR), hybridization, DNA sequencing, microarray, isothermal nucleic acid amplification technology (INAAT), and others (electrophoresis, mass spectroscopy, and flow cytometry). PCR contributed to the highest share in 2016, owing to the increase in usage in proteomics and genomics, which is highly cost-effective. Based on application, it is divided into infectious diseases, oncology, genetic testing, blood screening, and others (Microbiology, neurological diseases, and cardiovascular diseases). Infectious diseases accounted for the highest market share in 2016, owing to the increase in the number of patients suffering from infectious diseases.

Based on end user, it is categorized into hospitals, reference laboratories, and others (blood banks, home health agencies, and nursing homes). Hospitals accounted for the highest market share in the global market in 2016, owing to the increase in the number of patients treated in hospitals.

Top Investment Pockets

The global molecular diagnostics market is segmented by application into infectious diseases, oncology, genetic testing, blood screening, and others (microbiology, neurological diseases, and cardiovascular diseases). Infectious diseases projected the highest revenue in 2016, with a CAGR of 9.3% for the forecast period of 2017-2023, owing to increase in the number of patients suffering from different viral and bacterial infections, such as Human Immunodeficiency Virus (HIV), Hepatitis C virus(HCV), Human Papillomavirus(HPV), Chlamydia trachomatis/ Neisseria gonorrhoeae (CT/NG), and others. Along with the improving healthcare facilities treating these diseases in the emerging nations.

Geographically, the global molecular diagnostics market is segmented into North America, Europe, Asia-Pacific, and LAMEA. The North American molecular diagnostics market accounted for the highest market share in 2016, owing to the factors such as, large aging population, rise in number of cases of infectious and chronic diseases, and increase in awareness of personalized medicines. The European molecular diagnostics market is the second highest revenue generator, owing to well-penetrated healthcare system and favorable regulatory policies. The Asia-Pacific is expected to show the highest growth in the global molecular diagnostics market from 2017 to 2023, with an estimated CAGR of 10.1% owing to the improvement in healthcare facilities to treat the increasing patient population for infectious diseases and various types of cancer.

Request for Table of Content

Molecular diagnostics technique is used for analyzing biological markers at the molecular level, such as genome and proteome; for diagnosis of the various infectious diseases, cancer, and other diseases/disorders; and to check the risk of genetic predisposition for a disease.

The factors such as increase in the prevalence of the infectious diseases & various types of cancer; increase in awareness and acceptance of personalized medicines; growth in the biomarker identification; and advancement in molecular diagnostics drive the growth of the market. Stringent regulatory requirements for the approval of new molecular diagnostic techniques restrain the growth of the market. However, increase in adoption of the molecular diagnostics in the emerging economies provide growth opportunities for the market

There is an increase in the incidence of chronic diseases, such as tuberculosis (TB), cancer, cardiovascular diseases, and diabetes. In 2011, approximately 5 million deaths occurred due to these diseases (AIDS, malaria & TB). According to WHO, worldwide, cancer caused 7.9 million deaths in 2011, and is expected to reach 11 million by 2030. There are various types of cancers, such as bladder, breast, brain, cervical, kidney, lung, ovarian, pancreatic, skin, and typhoid. In addition, there is a substantial rise in the number of patients suffering from infectious diseases, such as gastrointestinal, respiratory, and STDs (sexually transmitted diseases). The increase in these diseases is expected to rise the demand for diagnostic devices, which drives the overall molecular diagnostics market.